{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:53:03Z","timestamp":1781502783011,"version":"3.54.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In recent years, novel drugs are available for the patients with relapsed\/refractory Hodgkin lymphoma (HL), like immune checkpoint inhibitors (CPi). These drugs have been able to rescue a cohort of patients who subsequently could receive an allogeneic stem\u2010cell transplant (SCT). No data were reported for subsequent autologous SCT (ASCT) after CPi. Here, we report our real\u2010life experience in heavily pretreated HL patients undergoing ASCT as consolidation approach after CPi treatment. A retrospective observational study was conducted. Patients had CPi therapy in the context of clinical trials (\n                    <jats:italic>n<\/jats:italic>\n                    = 6) or in the named patient program (\n                    <jats:italic>n<\/jats:italic>\n                    = 7) between July 2014 and November 2019: 9 out of 13 received pembrolizumab and the remaining four underwent nivolumab. A median of 12 cycles (range, 3\u201316) of CPi therapy were infused. Thirteen patients underwent ASCT after CPi: 11 (84.6%) patients obtained a complete response (CR) and 2 had progression of disease, with an overall response rate of 84.6%. With a median follow\u2010up of 3.3 years (range, 1.1\u20135.5), only one CR patient had disease relapse after 3.9 months from ASCT, leading to an estimated disease\u2010free survival of 87.5% at 56.9 months. The estimated 5\u2010year progression\u2010free survival was 73.4% and overall survival was 92.3% at 4.8 years, respectively. No unexpected or cumulative toxicity was observed. Our results indicated that ASCT may represent a further effective therapeutic option as consolidation in HL after CPi treatment that today represents the last conventionally recognized therapeutic line.\n                  <\/jats:p>","DOI":"10.1002\/hon.2803","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T03:51:39Z","timestamp":1599796299000},"page":"737-741","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed\/refractory Hodgkin lymphoma: A real\u2010life experience"],"prefix":"10.1002","volume":"38","author":[{"given":"Beatrice","family":"Casadei","sequence":"first","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Morigi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Lolli","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-7313","authenticated-orcid":false,"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nanni","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Elia","family":"Coppola","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Carella","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italia"},{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Universit\u00e0 degli Studi  Bologna Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"e_1_2_10_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_10_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_10_1_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_10_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_10_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_10_1_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_10_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_10_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.158"},{"key":"e_1_2_10_1_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385"},{"key":"e_1_2_10_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.028"},{"key":"e_1_2_10_1_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_10_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_1_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_2_10_1_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"e_1_2_10_1_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"e_1_2_10_1_17_1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0277-5379(90)90180-2","article-title":"BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non\u2010Hodgkin's lymphomas","volume":"26","author":"Colombat P","year":"1990","journal-title":"Eur J Canc"},{"key":"e_1_2_10_1_18_1","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2018-99-114502","article-title":"Nivolumab treatment beyond investigator\u2010assessed progression: extended follow\u2010up in patients with relapse\/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study","volume":"132","author":"Cohen JB","year":"2018","journal-title":"Blood"},{"key":"e_1_2_10_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-811174"},{"key":"e_1_2_10_1_20_1","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood.V128.22.3502.3502","article-title":"Outcomes of allogeneic hematopoietic stem\u2010cell transplantation (HSCT) after treatment with nivolumab for relapsed\/refractory Hodgkin lymphoma","volume":"128","author":"Armand P","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.003"},{"key":"e_1_2_10_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13186"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2803","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:11:01Z","timestamp":1781500261000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/hon.2803"],"URL":"https:\/\/doi.org\/10.1002\/hon.2803","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2803\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2803\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2803\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2803\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2803\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"2020-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}